Literature DB >> 23507237

Early administration of the first antimicrobials should be considered a marker of optimal care of patients with community-acquired pneumonia rather than a predictor of outcomes.

Jose Bordon1, Stefano Aliberti, Padmaraj Duvvuri, Timothy Wiemken, Paula Peyrani, Inez Natividad, Alfredo Caceres-Lara, Robert Delapenha, Francesco Blasi, Julio Ramirez.   

Abstract

BACKGROUND: The effect of time of the first antimicrobial dose (TFAD) on the outcomes of community-acquired pneumonia (CAP) remains a controversy.
METHODS: This was an observational, retrospective study of consecutive adult patients hospitalized with CAP. TFAD was defined as the time in hours from arrival at the emergency department to the intravenous infusion of antimicrobial. All patients received appropriate antibiotic therapy according to available Infectious Diseases Society of America/American Thoracic Society guidelines during the time of our study. Multivariable analysis and a propensity score adjusted methodology were used to measure the association of TFAD with mortality, time to clinical stability (TCS), and length of stay in the hospital (LOS).
RESULTS: Data of 372 patients with CAP were studied. A total 29 (8.4%) patients died within 30 days of hospitalization. Our propensity-adjusted logistic regression model did not show a significant association between TFAD and mortality (p=0.148). Patients who died received antimicrobials significantly earlier than survivors: 5.7h vs. 7.5h, respectively (p=0.04). The LOS and TCS were not significantly affected by the TFAD; the LOS hazard ratio was 0.996 (95% confidence interval 0.97-1.02; p=0.774) and the TCS hazard ratio was 1.01 (95% confidence interval 0.98-1.03; p=0.604).
CONCLUSIONS: TFAD does not seem to be associated with the clinical outcome of patients with CAP. Early TFAD should be considered as an important marker of optimal care of patients with CAP rather than as a factor predicting outcomes.
Copyright © 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23507237     DOI: 10.1016/j.ijid.2012.09.021

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  5 in total

1.  The Roles of the Charlson Comorbidity Index and Time to First Antibiotic Dose as Predictors of Outcome in Pneumococcal Community-Acquired Pneumonia.

Authors:  Daniel Franzen; Marisa Lim; Daniel J Bratton; Stefan P Kuster; Malcolm Kohler
Journal:  Lung       Date:  2016-07-12       Impact factor: 2.584

2.  Improved survival among ICU-hospitalized patients with community-acquired pneumonia by unidentified organisms: a multicenter case-control study.

Authors:  J Rello; E Diaz; R Mañez; J Sole-Violan; J Valles; L Vidaur; R Zaragoza; S Gattarello
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-09-21       Impact factor: 3.267

3.  Antimicrobial Stewardship with Pharmacist Intervention Improves Timeliness of Antimicrobials Across Thirty-three Hospitals in South Africa.

Authors:  Angeliki P Messina; Dena van den Bergh; Debra A Goff
Journal:  Infect Dis Ther       Date:  2015-09-11

4.  Improvement of antibiotic therapy and ICU survival in severe non-pneumococcal community-acquired pneumonia: a matched case-control study.

Authors:  Simone Gattarello; Leonel Lagunes; Loreto Vidaur; Jordi Solé-Violán; Rafael Zaragoza; Jordi Vallés; Antoni Torres; Rafael Sierra; Rosa Sebastian; Jordi Rello
Journal:  Crit Care       Date:  2015-09-10       Impact factor: 9.097

5.  Phenotyping community-acquired pneumonia according to the presence of acute respiratory failure and severe sepsis.

Authors:  Stefano Aliberti; Anna Maria Brambilla; James D Chalmers; Catia Cilloniz; Julio Ramirez; Angelo Bignamini; Elena Prina; Eva Polverino; Paolo Tarsia; Alberto Pesci; Antoni Torres; Francesco Blasi; Roberto Cosentini
Journal:  Respir Res       Date:  2014-03-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.